SCHEMBL16146282

SCHEMBL16146282

Oc1nc(NCc2ccccc2F)nc2nc[nH]c12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK1 P06493 2/20 0.46
ADORA3 P0DMS8 1/20 0.43
VNN1 O95497 1/20 0.42
KDM4E B2RXH2 2/20 0.42
LMNA P02545 1/20 0.41
ALOX15 P16050 1/20 0.41
HTT P42858 1/20 0.41
IP6K1 Q92551 2/20 0.40
PLK4 O00444 1/20 0.40
PAK4 O96013 1/20 0.40
MAPT P10636 1/20 0.39
HDAC1 Q13547 2/20 0.39
HDAC2 Q92769 2/20 0.39
PDE4A P27815 1/20 0.39
PDE4B Q07343 1/20 0.39
PDE4C Q08493 1/20 0.39
PDE4D Q08499 1/20 0.39
NTRK1 P04629 1/20 0.39
TP53 P04637 1/20 0.39
TSHR P16473 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30523381 1.00 CDK1 (0.46) CDK1ADORA3VNN1KDM4ELMNA
SCHEMBL30523459 0.85 POLA1 (0.45) CDK1ADORA3VNN1LMNAALOX15
SCHEMBL30523407 0.85 CDK1 (0.46) CDK1ADORA3LMNAALOX15HTT
SCHEMBL30523384 0.85 LMNA (0.58) CDK1ADORA3LMNAALOX15HTT
SCHEMBL16146662 0.85 CDK1 (0.46) CDK1ADORA3LMNAALOX15HTT
SCHEMBL16147253 0.85 POLA1 (0.45) CDK1ADORA3VNN1LMNAALOX15
SCHEMBL16147051 0.85 LMNA (0.58) CDK1ADORA3LMNAALOX15HTT
SCHEMBL30523463 0.82 CDK1 (0.43) CDK1ADORA3LMNAALOX15HTT
SCHEMBL16146612 0.82 CDK1 (0.43) CDK1ADORA3LMNAALOX15HTT
SCHEMBL16146805 0.81 HSD17B10 (0.61) CDK1KDM4ELMNAALOX15IP6K1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140303112-A1 Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) ENERGENESIS BIOMEDICAL CO., LTD (TW) 2014-10-09 US claimed
CN-116492347-A Compound for activating AMPK and application thereof 华安医学股份有限公司 2023-07-28 CN disclosed
US-9938279-B2 Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) ENERGENESIS BIOMEDICAL CO., LTD (TW) 2018-04-10 US disclosed
US-20140303112-A1 Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) ENERGENESIS BIOMEDICAL CO., LTD (TW) 2014-10-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140303112-A1 Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) PRKAG2, PRKAB2, PRKAG1 CDK1 2235/4885ADORA3 1280/4885VNN1 3865/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.